Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a nasal spray for intranasal use. It is indicated for the acute treatment of migraine attacks in adults and provides rapid relief of headache pain and associated symptoms. GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan) acts on the trigeminovascular pathway to relieve migraine and related headache disorders.

Migraine: provides rapid relief of headache pain, photophobia, phonophobia and nausea during an acute migraine attack. Cluster headache: aborts acute cluster headache episodes when administered at the onset of pain.

Common Side Effects: - Taste disturbance or metallic taste. - Nasal irritation or burning sensation. - Throat irritation or dryness. - Dizziness or light‑headedness. - Nausea or mild stomach upset.

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial infarction. - Stroke or transient ischemic attack. - Severe hypertension or hypertensive crisis. - Anaphylactic or severe allergic reactions. - Serotonin syndrome, especially when combined with other serotonergic agents.

Before using Imigran, consider the following precautions: - Cardiovascular disease: avoid if you have known coronary artery disease, angina, or recent myocardial infarction. - Uncontrolled hypertension: do not use if blood pressure is not well managed. - History of stroke or hemiplegic migraine: contraindicated. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: may cause additive vasoconstriction. - SSRIs, SNRIs, or other serotonergic agents: increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan exposure. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy of sumatriptan.